NVLS Nivalis Therapeutics Inc.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Nivalis Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Nivalis Therapeutics, Inc. (“Nivalis Therapeutics” or the “Company”) (NASDAQ:NVLS) concerning possible violations of federal securities laws by certain officers and directors.

On November 28, 2016, Nivalis Therapeutics announced that the Company’s Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at 12 weeks, in comparison to placebo. Following this news, shares of Nivalis Therapeutics were down more than 59% on intraday trading on November 29, 2016. To obtain additional information about the investigation, go to:

http://zlk.9nl.com/nivalis-therapeutics-nvls

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
29/11/2016

Underlying

NVLSNivalis Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nivalis Therapeutics Inc.

 PRESS RELEASE
Free
NVLS Nivalis Therape...

Nivalis Therapeutics Announces Results of Special Meeting of Stockhold...

BOULDER, Colo.--(BUSINESS WIRE)-- Nivalis Therapeutics, Inc. (Nivalis) (Nasdaq: NVLS) announced today that, based upon the final vote count certified by the independent inspector of elections for the special meeting of stockholders held July 19, 2017, its stockholders approved all of the merger-related proposals, including: (i) the Agreement and Plan of Merger and Reorganization, dated as of April 18, 2017, by and among Nivalis, Nautilus Merger Sub, Inc. and Alpine Immune Sciences, Inc. (Alpine), and the transactions contemplated by t...

July 20, 2017 1 EN
 PRESS RELEASE
Free
NVLS Nivalis Therape...

Nivalis Therapeutics Reports First Quarter 2017 Financial Results

BOULDER, Colo.--(BUSINESS WIRE)-- Nivalis Therapeutics, Inc. (NASDAQ: NVLS), a pharmaceutical company historically focused on developing innovative solutions for people with cystic fibrosis (CF), today reported financial results and recent business highlights for the first quarter 2017. In April, Nivalis and Alpine Immune Sciences, Inc., a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, announced that they had entered into a definitive merger agreement under ...

May 1, 2017 1 EN
 PRESS RELEASE
Free
NVLS Nivalis Therape...

Nivalis Therapeutics, Inc. and Alpine Immune Sciences, Inc. Agree to C...

BOULDER, Colo. & SEATTLE--(BUSINESS WIRE)-- Nivalis Therapeutics, Inc. (NASDAQ: NVLS) and Alpine Immune Sciences, Inc., a privately-held biotechnology company developing novel therapies using its next-generation immune system modulation platform, today jointly announced they have entered into a definitive merger agreement under which Alpine will merge with a wholly-owned subsidiary of Nivalis in an all-stock transaction. The merger will result in a combined company with a novel protein-based discovery platform focused on inflammation ...

April 18, 2017 1 EN
 PRESS RELEASE
Free
NVLS Nivalis Therape...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of...

NEW YORK--(BUSINESS WIRE)-- Levi & Korsinsky announces it has commenced an investigation of Nivalis Therapeutics, Inc. (“Nivalis Therapeutics” or the “Company”) (NASDAQ:NVLS) concerning possible violations of federal securities laws by certain officers and directors. On November 28, 2016, Nivalis Therapeutics announced that the Company’s Phase 2 Trial of Cavosonstat failed to meet its primary endpoint of demonstrating a benefit in the absolute change in percent-predicted FEV1 (lung function) or in sweat chloride reduction at ...

November 29, 2016 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch